3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Renal Cell
25
Neoplasms
9
Kidney Neoplasms
8
Prostatic Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Carcinoma, Hepatocellular
6
Colorectal Neoplasms
4
Carcinoma, Medullary
4
Carcinoma
4
Triple Negative Breast Neoplasms
2
Thyroid Neoplasms
2
Pain
2
Ovarian Neoplasms
2
Liver Neoplasms
2
von Hippel-Lindau Disease
1
Urologic Neoplasms
1
Thyroid cancer, follicular
1
Thyroid Cancer, Papillary
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Recurrence
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neoplasm Metastasis
1
Mesothelioma
1
Melanoma
1
Kidney Diseases
1
Head and Neck Neoplasms
1
Glioma
1
Glioblastoma
1
Interventions
belzutifan
4
Everolimus
2
vatalanib
1
spartalizumab
1
palbociclib
1
lenvatinib
1
cabozantinib
1
PT2385
1
Nivolumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
von Hippel-Lindau Disease
×
cabozantinib
×
Clear all
NCT07405164
2026-05-29
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3
Recruiting
450 enrolled